Investors & Media
Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at
“During the second quarter and subsequent period, we took a significant
step forward in the development of our lead program, DCR-PHXC, as well
as our broad pipeline of novel GalXCTM-based therapeutics,”
GalXC™ Pipeline Update
Primary Hyperoxaluria (PH): Dicerna continued to advance the PHYOX
Phase 1 clinical trial of DCR-PHXC, which is in development to treat
all forms of PH. PHYOX is a single-ascending dose study of DCR-PHXC in
normal healthy volunteers (NHVs) and patients with PH. PH is a family
of severe, rare, genetic liver disorders characterized by
overproduction of oxalate that often results in kidney failure.
May 2018, Dicerna dosed the first PH patient with DCR-PHXC in the Group B portion of the PHYOX study. Group B is an open-label, multi-center study enrolling up to 16 patients with PH1 and PH2. Group B consists of three cohorts of patients with PH1 dosed at 1.5, 3 and 6 mg/kg, and an additional fourth cohort that consists of patients with PH2 dosed at flexible dosing levels. The fourth cohort runs in parallel to the other three cohorts. Dicerna has dosed 10 out of 16 patients in Group B—four PH1 patients in Cohort 1, four PH1 patients in Cohort 2, one PH1 patient in Cohort 3, and one PH2 patient in Cohort 4.
- Dicerna completed the Group A portion of the study in NHVs. Group A is a placebo-controlled, single-blind, single center study that enrolled 25 NHVs. While the study remains blinded to treatment assignment, topline results from Group A evidence no serious adverse events (SAEs). There have been two mild-to-moderate transient injection site reactions at doses of 6 and 12 mg/kg involving erythema and tenderness lasting no more than 36 hours.
- The primary objective of PHYOX is to evaluate the safety and tolerability of single doses of DCR-PHXC in NHVs and patients with PH. The secondary objectives are to evaluate the pharmacodynamic effect of single doses of DCR-PHXC on urinary oxalate concentrations, as well as other biochemical markers, and to characterize the pharmacokinetics of single doses of DCR-PHXC in both groups.
- Dicerna expects to report interim results from the PHYOX trial later in the third quarter and publicly present trial results in the fourth quarter of 2018. The Company intends to initiate a multi-dose Phase 2/3 study of DCR-PHXC in the first quarter of 2019, pending positive proof-of-concept data and regulatory feedback.
May 2018, the U.S. Food and Drug Administrationgranted Orphan Drug Designation to DCR-PHXC for the treatment of PH.
July 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products recommended designating DCR-PHXC as an orphan medicinal product for the treatment of PH in the European Unionand the recommendation was adopted by the European Commissionin August 2018.
Chronic Hepatitis B Virus (HBV): Dicerna expects to file regulatory
clearances for human clinical trials in
New Zealandand Australiafor DCR-HBVS, in development for the treatment of chronic HBV, during the fourth quarter of 2018. If the clearances are granted, the Company intends to begin clinical studies shortly thereafter.
- Undisclosed Rare Disease Involving the Liver: Dicerna is actively seeking a risk-sharing collaborator for this second program focused on a serious rare disease, before it files regulatory clearances to initiate a clinical trial. For competitive reasons, the Company has not yet publicly disclosed the target gene or disease.
- NASH Collaboration with Boehringer Ingelheim (BI): Dicerna continued to advance the program, initially focused on nonalcoholic steatohepatitis (NASH), in accordance with the work plan for this collaboration.
Conclusion of Litigation
April 18, 2018, Dicernaand Alnylam Pharmaceuticalsentered into a Confidential Settlement Agreement and General Release (the Settlement Agreement), resolving all ongoing litigation between the two companies. The terms of the Settlement Agreement include mutual releases and dismissals with prejudice of all claims and counterclaims in the litigation between Dicerna and Alnylam and neither party admitted wrongdoing as part of the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, Dicerna paid to Alnylam an upfront payment of $2.0 million, agreed to a future payment of $13.0 millionand issued 983,208 shares of common stock to Alnylam.
The Settlement Agreement does not include any licenses to any intellectual property from either party and does not include any royalties or milestones related to product development. For additional detail, please see Dicerna’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2018, which was filed with the Securities and Exchange Commission( SEC) on August 8, 2018.
Financial Condition and Operating Results
- Cash Position – As of
June 30, 2018, Dicerna had $82.3 millionin cash and cash equivalents and held-to-maturity investments, as compared to $113.7 millionin cash and cash equivalents and held-to-maturity investments as of December 31, 2017. Additionally, the Company had $0.7 millionof restricted cash equivalents as of June 30, 2018and December 31, 2017, which reflects collateral securing the Company’s operating lease obligation.
- Revenue – Dicerna recognized
$1.5 millionand $3.1 millionof revenue associated with the BI Agreement, during the three and six months ended June 30, 2018, respectively. The revenue primarily represents partial amortization of the $10.0 millionnon-refundable upfront payment from BI, as well as certain reimbursable third-party research expenses which are billable to BI. Dicerna expects to recognize the remainder of the initial transaction price on a straight-line basis through June 30, 2019. Dicerna does not expect to generate any product revenue for the foreseeable future.
- Research and Development (R&D) Expenses – R&D expenses were
$10.3 millionand $20.2 millionfor the three and six months ended June 30, 2018, respectively, as compared to $9.1 millionand $17.8 millionfor the same periods in 2017. The increase was due to higher direct R&D expenses, partially offset by a reduction in platform-related expenses.
The increase in the three months ended
June 30, 2018was primarily due to an increase in clinical study costs and an increase in R&D salaries due to an increase in R&D headcount compared to the same period in 2017. The increase in the six months ended June 30, 2018was primarily due to an increase in toxicology studies and an increase in clinical studies.
The decrease in platform-related expenses for the three and six months ended
June 30, 2018was primarily due to lab material and supply costs and contract research costs associated with applying the Company’s GalXC platform against gene targets.
- General and Administrative (G&A) Expenses – G&A expenses
$4.8 millionand $9.1 millionfor the three and six months ended June 30, 2018, respectively, as compared to $4.1 millionand $8.2 millionfor the same periods in 2017. The increase is predominantly related to higher consulting and corporate legal expenses.
- Litigation Expenses – Litigation expenses, all related to the
litigation with Alnylam, were
$22.2 millionand $25.4 millionfor the three and six months ended June 30, 2018, respectively, as compared to $2.2 millionand $3.6 millionfor the same periods in 2017. The increase is predominantly due to the $21.0 millionof settlement expenses related to the litigation settlement recorded in the second quarter of 2018.
- Net Loss Attributable to Common Stockholders – Net loss
attributable to common stockholders was
$35.6 millionand $51.2 millionfor the three and six months ended June 30, 2018, respectively, as compared to $24.0 millionand $38.2 millionfor the same periods in 2017. The increase is attributable to higher operating expenses, including the $21.0 millionin litigation settlement expenses, partially offset by higher revenues, interest income and a decrease in dividends as a result of the conversion of the redeemable convertible preferred stock in December 2017.
For more detailed information and analysis, see Dicerna’s Quarterly
Report on Form 10-Q for the quarter ended
Dicerna believes that it has sufficient cash to fund the execution of its current clinical and operating plan through 2019, which includes advancing DCR-PHXC through proof-of-concept trials and into late-stage clinical development and initiating proof-of-concept studies of DCR-HBVS in patients with HBV. This estimate assumes no new funding from additional collaboration agreements or from external financing events.
Management will host a conference call at
About GalXCTM RNAi Technology Platform
GalXCTM is a proprietary technology platform invented by Dicerna to discover and develop RNAi-based therapies designed to silence disease-driving genes in the liver. Compounds produced via GalXC are intended to be broadly applicable across multiple therapeutic areas, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Using GalXC, Dicerna scientists attach N-acetylgalactosamine sugars directly to the extended region of the Company’s proprietary RNAi molecules, yielding multiple proprietary conjugate delivery configurations. Many of the conjugates produced via GalXC incorporate a folded motif known as a tetraloop in the extended region. The tetraloop configuration, which is unique to Dicerna’s GalXC compounds, allows flexible and efficient conjugation to the targeting ligands, and stabilizes the RNAi duplex which the Company believes will enable subcutaneous delivery of its RNAi therapies to hepatocytes in the liver, where they are designed to specifically bind to receptors on target cells, potentially leading to internalization and access to the RNAi machinery within the cells. The technology may offer several distinct benefits, as suggested by strong preclinical data. The benefits seen in preclinical studies include: potency that is on par with or better than comparable platforms; highly specific binding to gene targets; long duration of action; and an infrequent subcutaneous dosing regimen.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including, for example, Dicerna’s expected timeline and plans for development of DCR-PHXC and other pipeline programs, expectations related to the collaboration with BI, expectations for discussions and possible opportunities with potential partners and collaborators, and guidance related to the anticipated duration and usage of current cash and cash equivalents. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include risks relating to Dicerna’s clinical and preclinical research and other risks identified under the heading "Risk Factors" included in the Company’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
|Dicerna Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheet Information|
|(Unaudited, in thousands)|
|June 30,||December 31,|
|Cash and cash equivalents||$||42,426||$||68,789|
|Total stockholders’ equity||$||64,575||$||101,086|
|Dicerna Pharmaceuticals, Inc.|
|Condensed Consolidated Statements of Operations Information|
|(Unaudited, in thousands, except share and per share data)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Revenue from collaborative arrangements||$||1,545||$||—||$||3,090||$||—|
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Total other income, net
Dividends on redeemable convertible
Deemed dividend related to beneficial
conversion feature of redeemable
convertible preferred stock
Net loss attributable to common
Net loss per share attributable to
common stockholders— basic
Weighted average common shares
outstanding—basic and diluted